Enzymatica AB: Interim report Q4/2022: A year that laid the foundation for growth

Significant events during the quarter

Significant events after the quarter

• On October 31, the journal Respiratory Research
  published an in-vitro study from the Medical University of
  Innsbruck which shows that ColdZyme blocks the
  widespread and highly transmissible omicron variants
  BA.4 and BA.5 from adhering to and infecting human
  cells. According to the researchers who conducted the
  study, this finding means the possibility that ColdZyme
  can be applied to prevent the spread of SARS-CoV-2.
  Continued clinical trials are needed to confirm the effect
  in-vivo.

• No significant events were reported after the end of the quarter.

Other events during the quarter

• In November, the University of Kent (UK) initiated a double-blind, placebo-controlled clinical study to explore the
  preventative effects of ColdZyme on upper respiratory tract infections in elite athletes. The study builds on a
  previous 2020 study from the same research group, which showed that treatment with ColdZyme can reduce the
  number of lost training days. The goal is to present the study in the fall of 2023 before the upcoming cold season.

Fourth quarter

January-December

• Net sales reached SEK 16.6 (18.7) million.

• The operating result totaled SEK -21.6 (-10.5) million.

• The operating result includes non-recurring expenses of
  SEK 5.6 million attributable to the renegotiation of
  contracts with one of the company's partners.

• Earnings per share, basic and diluted, were SEK -0.14
  (-0.07).

• Cash flow from operating activities totaled SEK -27.7
  (-6.6) million. Cash flow was affected by payment of one-
  off compensation to partners totaling SEK 18.5 million.

• Net sales reached SEK 48.9 (57.2) million.

• The operating result totaled SEK -68.2 (-45.2) million.

• The operating result includes non-recurring
  expenses of SEK 14.2 million attributable to the
  renegotiation of contracts with two of the company's partners.

• Earnings per share, basic and diluted, were SEK -0.44 (-0.31).

• Cash flow from operating activities for the period
  totaled SEK -65.4 (-35.9) million. Cash flow was
  impacted by payment of the one-off compensation
  to partners totaling SEK 18.5 million.

• Cash flow from financing activities totaled SEK 88.2
  million, of which SEK 69.0 million relates to the
  rights issue in September.

• Net cash totaled SEK 28.4 (29.0) million.